2022-502837-24-00招募中3 期
J2A-MC-GZGQ: A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight and Type 2 Diabetes (ATTAIN-2)
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 390
- 试验地点
- 35
- 主要终点
- Mean Percent Change from Baseline in Body Weight (from Baseline to Week 72)
研究概览
简要总结
To demonstrate that LY3502970 is superior to placebo in change from baseline for body weight.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- •Be overweight or have excess weight.
- •Have history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
- •Have type 2 diabetes and on stable treatment for Type 2 diabetes for at least 90 days prior to screening.
- •Have been taking up to 3 oral anti-hyperglycemic medications
排除标准
- •Have type 1 diabetes or any other type of diabetes except type 2
- •Have a change in body weight more than 11 pounds within 90 days before screening.
- •Have medullary thyroid cancer or multiple endocrine neoplasia type 2
- •Have a history of chronic or acute pancreatitis
- •Have diabetic retinopathy and/or macular edema requiring acute treatment.
- •Have active or untreated cancer for less than 5 years.
结局指标
主要结局
Mean Percent Change from Baseline in Body Weight (from Baseline to Week 72)
Mean Percent Change from Baseline in Body Weight (from Baseline to Week 72)
次要结局
未报告次要终点
研究者
Lilly Clinical Trials information desk
Scientific
Eli Lilly & Co.
研究点 (35)
Loading locations...
相似试验
招募中
2 期
An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid ArthritisRheumatoid Arthritis2022-502994-40-00Eli Lilly & Co.62
招募中
3 期
Study of setmelanotide in patients with obesity with specific genetic variants2023-507634-24-00Rhythm Pharmaceuticals Inc.85
招募中
2 期
A Phase 2, Double-Blinded, Randomized, Placebo-Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of GS-5290 in Participants With Moderately to Severely Active Ulcerative ColitisUlcerative Colitis2022-501119-14-01Gilead Sciences Inc.78
招募中
3 期
A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee (TRIUMPH-4)Osteoarthritis, KneeObesity2023-503660-17-00Eli Lilly & Co.65
招募中
2 期
A Study of LY3457263 Compared to Placebo in Participants with Type 2 Diabetes on a Stable Dose of Semaglutide or TirzepatideType 2 Diabetes2024-520328-27-00Eli Lilly & Co.20